BELMONT, Calif. and BASEL, Switzerland, March 2, 2018 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX:RHHBY), announces today two major milestones in the evolution of the Decision Support platform being developed in its Diagnostics Information Solutions (DIS) business.
The first milestone is HITRUST CSF (Certifiable Security Framework) certification after an audit specific to the NAVIFY Tumor Board solution, DIS' inaugural offering launched last October. HITRUST CSF certification, granted January 18th, centers on cybersecurity in healthcare and is highly valued, especially in the United States.
Click here to download our cloud security brochure.
The Roche DIS Belmont site also received ISO/IEC 27001 certification, which pertains to secure and compliant data handling. This is significant support to enable entry into European and Asian markets. Both of these certifications and their impact on patient data safety are timely subjects of discussion at the upcoming Health Information and Management Systems Society held March 5-9 in Las Vegas. Roche will have shared presence at the Accenture, Amazon Web Services (AWS), and ClearDATA partner booths where presentations on healthcare data security and demonstrations of the NAVIFY Tumor Board solution will be given. To learn more about Roche's presence at HIMSS, click here.
HITRUST CSF and ISO/IEC 27001 certifications call for accountability partners to continuously and independently review Roche's data protection protocols. These certifications affirm Roche's commitment to the highest standards of data care that allow the assurance of patient data protection while offering new, innovative products to their customers. These achievements also reflect Roche's Code of Conduct, including corporate responsibility, integrity, and respect for patient privacy. More in-depth technical information on these certifications can be found on the HITRUST and ISO/IEC 27001 organisations' web sites.
"With these two certifications, we have the quality marks customers look for," said Tim M. Jaeger, Global Head of Diagnostics Information Solutions. "Our customers' trust is sacred to us because we know just how important patient data is to all parties involved."
In addition to ongoing updates to the NAVIFY Tumor Board solution, additional products and applications are currently under development to build a world-class, integrated Decision Support portfolio. Through HITRUST CSF and ISO/IEC 27001 certifications, recognised information security standards and a flexible framework for prescriptive and scalable security controls help ensure patient data remains secure across the entire platform.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche Diagnostics Information Solutions Media Contact
Phone: (925) 699-1263 / e-mail: email@example.com
- James Green
SOURCE Roche | Diagnostics Information Solutions